March 7th 2022November 1st 2021 Shorla Oncology at CPhI Worldwide in Milan Read more at: https://www.cphi.com/europe/en/home.html
Shorla Oncology at ASH Annual Meeting and ExpositionNovember 21st 2023Read More Shorla Oncology at ASH Annual Meeting and Exposition
Shorla Oncology attending Jefferies Healthcare ConferenceOctober 31st 2023Read More Shorla Oncology attending Jefferies Healthcare Conference
PRESS RELEASE: Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from TherakindOctober 31st 2023Read More PRESS RELEASE: Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind
Goodman-backed Shorla Oncology secures $35m in Series-B fundingOctober 24th 2023Read More Goodman-backed Shorla Oncology secures $35m in Series-B funding
Shorla Oncology raises $35m to accelerate growthOctober 24th 2023Read More Shorla Oncology raises $35m to accelerate growth
Raising Funds in a Tight Market: Q&A With Sharon Cunningham, CEO of Shorla OncologyOctober 24th 2023Read More Raising Funds in a Tight Market: Q&A With Sharon Cunningham, CEO of Shorla Oncology
Shorla Oncology at CPhI Barcelona 2023October 10th 2023Read More Shorla Oncology at CPhI Barcelona 2023
PRESS RELEASE: Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product PortfolioOctober 4th 2023Read More PRESS RELEASE: Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio
